Overview
Empirico uses human genetics and large biological datasets to discover and develop new medicines, focusing on target discovery and collaborations. Its Precision Insights Platform analyzes genetic and health data from millions of individuals using curated data, custom models, and proprietary algorithms to generate and rank high-confidence therapeutic hypotheses. It differentiates itself by grounding drug targets in naturally occurring genetic variation and by pairing a large dataset with partner-driven experiments (e.g., AbCellera) to validate hypotheses. Its goal is to improve the success rate of drug development by identifying validated targets and translating them into medicines through collaborations.
Work here?Claim your company
Simplify's Take
What believers are saying
- EMP-012 reached phase I and secured an $85 million upfront GSK payment.
- The GSK deal extends EMP-012 into broader inflammatory respiratory indications beyond COPD.
- AbCellera collaboration broadens target discovery, supporting a capital-efficient partnering model.
What critics are saying
- GSK now owns EMP-012 commercialization, shrinking Empirico’s future revenue capture after phase I.
- Empirico’s public pipeline stays thin: one clinical asset and three preclinical programs.
- If EMP-012 disappoints in COPD, Empirico loses its clearest value-creation event.
What makes Empirico unique
- Empirico turns human genetics into siRNA medicines, not broad screening guesses.
- Its Precision Insights Platform prioritizes genetically validated targets across millions of human records.
- GSK licensed EMP-012 in October 2025, validating Empirico’s discovery engine.
Help us improve and share your feedback! Did you find this helpful?